8-K: Arcadia Biosciences Changes Auditors Amidst Internal Control Concerns

Arcadia Biosciences, Inc. has dismissed Deloitte & Touche LLP as its independent auditor and appointed Ramirez Jimenez International CPAs (RJI) as its successor.

Summary

• Arcadia Biosciences, Inc. announced on March 30, 2026, the dismissal of Deloitte & Touche LLP as its independent registered public accounting firm.
• The dismissal was approved by the company's Audit Committee.
• Deloitte's audit reports for the years ended December 31, 2025, and December 31, 2024, included an explanatory paragraph regarding the company's ability to continue as a going concern due to accumulated deficit, recurring net losses, and insufficient cash resources.
• The company identified material weaknesses in its internal control over financial reporting for the year ended December 31, 2025, related to insufficient segregation of duties and inadequate information system controls.
• These weaknesses were exacerbated by a reduction in employee headcount, impacting the effectiveness of business processes and information systems controls.
• Ramirez Jimenez International CPAs (RJI) has been engaged as the new independent registered public accounting firm, effective immediately.
• RJI will begin with the review of financial statements for the quarter ending March 31, 2026, and the audit for the year ending December 31, 2026.
• Deloitte & Touche LLP has confirmed they agree with the statements made by Arcadia Biosciences regarding their dismissal.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the dismissal of the auditor, the identification of material weaknesses in internal controls, and the explicit mention of going concern issues.

Positives

• Appointment of a new independent auditor (RJI) to provide fresh oversight.
• The company has provided Deloitte with a copy of the disclosures and requested their agreement with the statements made, indicating transparency.
• Deloitte & Touche LLP has confirmed they agree with the statements made by Arcadia Biosciences regarding their dismissal.

Negatives

• Dismissal of Deloitte & Touche LLP as the independent auditor.
• Deloitte's audit reports highlighted concerns about Arcadia Biosciences' ability to continue as a going concern due to accumulated deficit, recurring net losses, and insufficient cash.
• Material weaknesses in internal control over financial reporting were identified for the year ended December 31, 2025.
• These weaknesses stem from insufficient segregation of duties and inadequate information system controls.
• Reduced employee headcount has contributed to the control deficiencies.
• The company's financial statements for the years ended December 31, 2025, and December 31, 2024, contained an explanatory paragraph regarding going concern issues.

Risks

• The company's ability to continue as a going concern due to accumulated deficit, recurring net losses, and insufficient cash resources.
• Material weaknesses in internal control over financial reporting could lead to future misstatements or errors.
• The impact of reduced employee headcount on operational efficiency and financial reporting accuracy.
• Potential challenges in establishing a strong working relationship with the new auditor, RJI, especially concerning the remediation of identified control weaknesses.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. The engagement of a new auditor and the focus on internal controls suggest an effort to improve financial reporting reliability.

Management Comments

• The company identified material weaknesses in its internal control over financial reporting stemming from control deficiencies relating to insufficient segregation of duties in the financial statement close process and insufficient information system controls, including access and change management controls.
• The company's employee headcount has been reduced, resulting in insufficient personnel to maintain proper segregation of duties, which impacts the effectiveness of business process as well as information systems controls.

Industry Context

StockSavvy.ai notes that changes in independent auditors, particularly when accompanied by disclosures of material weaknesses in internal controls and going concern warnings, are significant events that can impact investor confidence and require close scrutiny. This situation is not uncommon for companies undergoing financial restructuring or facing operational challenges.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact on stock price due to concerns about financial reporting integrity and going concern status. Increased scrutiny of management's ability to rectify control issues.
• Creditors: May face increased risk if the company's financial health deteriorates further due to control weaknesses or ongoing losses.
• Employees: The mention of reduced headcount contributing to control deficiencies could indicate ongoing staffing challenges or restructuring efforts, potentially impacting morale and workload.

Next Steps

• The new auditor, RJI, will conduct a review of the company's financial statements for the quarter ending March 31, 2026.
• RJI will perform the audit of the company's consolidated financial statements for the year ending December 31, 2026.
• The company will likely need to implement remediation plans to address the identified material weaknesses in internal controls.

Key Dates

Recommendation

While the auditor change and internal control issues are concerning, the filing itself does not provide enough financial performance data to warrant a sell recommendation. However, the going concern warning and material weaknesses necessitate a cautious 'hold' stance until remediation efforts and future financial performance can be assessed.

Keywords

Arcadia Biosciences, Form 8-K, Auditor Change, Deloitte & Touche LLP, Ramirez Jimenez International CPAs, Internal Controls, Going Concern, Financial Reporting